Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Nrf2 inhibitors to overcome chemoresistance

Simon Crabb • 15 Feb 2019
GU Cancers 2019
Bladder Cancer Genitourinary Cancer Cisplatin

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, talks about targeting Nrf2 signaling pathways to overcome resistance to chemotherapeutic agents in bladder cancer. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Simon Crabb

1:25
ProCAID: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mCRPC
Simon Crabb • 19 Feb 2022
0:50
Maintenance therapy for patients with advanced urothelial carcinoma
Simon Crabb • 19 Feb 2022
1:36
ATLANTIS rucaparib arm: maintenance PARPi following chemotherapy for mUC
Simon Crabb • 19 Feb 2022
1:35
PARP inhibitors for the treatment of metastic castration-resistant prostate cancer
Simon Crabb • 19 Feb 2022

Related Videos

2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals